Enlivex Therapeutics (ENLV) Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
Go back to Enlivex Therapeutics (ENLV) Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update| Enliven Marketing Technologies Corporation (NASDAQ: ENLV) | Delayed: 1.49 -0.01 (0.67%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.50 | 52 Week High | $0.94 | |||
| Open | $1.45 | 52 Week Low | $0.47 | |||
| Day High | $1.49 | P/E | N/A | |||
| Day Low | $1.44 | EPS | $-0.11 | |||
| Volume | 32,321 | |||||
